KEYMED BIOSCIENCES -0001 (F:64Z) — Market Cap & Net Worth
Market Cap & Net Worth: KEYMED BIOSCIENCES -0001 (64Z)
KEYMED BIOSCIENCES -0001 (F:64Z) has a market capitalization of $2.59 Billion (€2.22 Billion) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #5368 globally and #852 in its home market, demonstrating a -5.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying KEYMED BIOSCIENCES -0001's stock price €7.85 by its total outstanding shares 294599566 (294.60 Million). Also see 64Z asset base for a full breakdown of the balance sheet.
KEYMED BIOSCIENCES -0001 Market Cap History: 2022 to 2026
KEYMED BIOSCIENCES -0001's market capitalization history from 2022 to 2026. Data shows growth from $2.08 Billion to $2.70 Billion (30.08% CAGR). Also see KEYMED BIOSCIENCES -0001 operating cash flow efficiency for how efficiently the company converts equity into cash flow.
KEYMED BIOSCIENCES -0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how KEYMED BIOSCIENCES -0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check KEYMED BIOSCIENCES -0001 (64Z) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.69x
KEYMED BIOSCIENCES -0001's market cap is 2.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $2.08 Billion | $100.06 Million | -$308.12 Million | 20.82x | N/A |
| 2023 | $1.88 Billion | $354.10 Million | -$359.36 Million | 5.30x | N/A |
| 2024 | $1.23 Billion | $428.12 Million | -$515.24 Million | 2.86x | N/A |
| 2025 | $1.93 Billion | $716.31 Million | -$522.64 Million | 2.69x | N/A |
Competitor Companies of 64Z by Market Capitalization
Companies near KEYMED BIOSCIENCES -0001 in the global market cap rankings as of September 19, 2026. Review KEYMED BIOSCIENCES -0001 tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to KEYMED BIOSCIENCES -0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
KEYMED BIOSCIENCES -0001 Historical Marketcap From 2022 to 2026
Between 2022 and today, KEYMED BIOSCIENCES -0001's market cap moved from $2.08 Billion to $ 2.70 Billion, with a yearly change of 30.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.70 Billion | +40.18% |
| 2025 | €1.93 Billion | +57.30% |
| 2024 | €1.23 Billion | -34.68% |
| 2023 | €1.88 Billion | -9.92% |
| 2022 | €2.08 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of KEYMED BIOSCIENCES -0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.59 Billion USD |
| MoneyControl | $2.59 Billion USD |
| MarketWatch | $2.59 Billion USD |
| marketcap.company | $2.59 Billion USD |
| Reuters | $2.59 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About KEYMED BIOSCIENCES -0001
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis;… Read more